

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Condensed Balance Sheets(Reviewed, Not Audited)**  
**Nine Months Ended September 30, 2017 and 2016**

Unit : NT\$ Thousands

Assets		September 30, 2017		December 31, 2016		September 30, 2016	
		Amount	%	Amount	%	Amount	%
<b>Current Assets</b>							
1100	Cash and Cash Equivalents	\$ 775,419	8	\$ 628,746	6	\$ 684,853	7
1147	Current Investments in Debt Instrument						
	Without Active Market	3,000	-	12,000	-	16,000	-
1150	Notes Receivable	298,239	3	391,559	4	338,432	3
1160	Notes Receivable – Related Parties	194,322	2	163,749	2	190,035	2
1170	Accounts Receivable	1,207,466	12	1,122,244	11	1,077,533	11
1180	Accounts Receivable – Related Parties	51,203	-	90,470	1	53,538	1
1200	Other Receivables	31,761	-	32,798	-	53,416	1
1210	Other Receivables –Related Parties	182,966	2	183,022	2	181,065	2
1220	Current Income Tax Assets	3	-	18,512	-	18,512	-
130X	Inventories	1,683,700	17	1,604,663	16	1,499,779	15
1410	Prepayments	123,265	1	61,452	1	73,065	1
1476	Other Financial Assets- Current	25,960	-	16,472	-	16,864	-
11XX	<b>Total Current Assets</b>	<u>4,577,304</u>	<u>45</u>	<u>4,325,687</u>	<u>43</u>	<u>4,203,092</u>	<u>43</u>
<b>Non-Current assets</b>							
1523	Available-for-sale Financial Assets- Noncurrent	279,663	3	252,205	3	273,633	3
1543	Financial Assets at Cost - Noncurrent	30,710	-	30,710	-	30,710	-
1550	Long-term Investments at Equity	785,063	8	811,821	8	797,117	8
1600	Property, Plant and Equipment	4,060,910	40	4,162,002	42	4,192,400	43
1780	Intangible Assets	30,540	-	34,493	-	7,936	-
1840	Deferred Tax Assets	132,587	2	145,637	2	132,917	1
1900	Other Non-current Assets	190,797	2	194,562	2	167,130	2
15XX	<b>Total Non-Current Assets</b>	<u>5,510,270</u>	<u>55</u>	<u>5,631,430</u>	<u>57</u>	<u>5,601,843</u>	<u>57</u>
1XXX	<b>Total Assets</b>	<u>\$ 10,087,574</u>	<u>100</u>	<u>\$ 9,957,117</u>	<u>100</u>	<u>\$ 9,804,935</u>	<u>100</u>

(Continue)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Condensed Balance Sheets(Reviewed, Not Audited)**  
**Nine Months Ended September 30, 2017 and 2016**

Unit : NT\$ Thousands

Liabilities and Shareholders' Equity		September 30, 2017		December 31, 2016		September 30, 2016	
		Amount	%	Amount	%	Amount	%
<b>Current Liabilities</b>							
2100	Short-term Borrowings	\$ 1,071,201	11	\$ 1,060,620	11	\$ 1,062,033	11
2110	Short-Term Notes and Bills Payable	91,500	1	115,994	1	84,994	1
2150	Notes Payable	117,875	1	82,352	1	84,306	1
2170	Accounts Payable	732,718	7	638,345	6	618,228	6
2200	Other Payables	298,819	3	371,642	4	268,987	3
2230	Current Income Tax Liabilities	23,379	-	27,376	-	22,448	-
2250	Short-term Provisions	78,244	1	68,115	1	63,027	1
2300	Other Current Liabilities	201,504	2	64,411	1	27,937	-
21XX	<b>Total Non-Current Liabilities</b>	<u>2,615,240</u>	<u>26</u>	<u>2,428,855</u>	<u>25</u>	<u>2,231,960</u>	<u>23</u>
<b>Non-Current Liabilities</b>							
2540	Long-term Borrowings	1,560,000	16	1,640,000	16	1,718,000	18
2570	Deferred Income Tax Liabilities	120,361	1	122,281	1	117,896	1
2600	Other Non-Current Liabilities	227,849	2	267,656	3	221,906	2
25XX	<b>Total Non-Current Liabilities</b>	<u>1,908,210</u>	<u>19</u>	<u>2,029,937</u>	<u>20</u>	<u>2,057,802</u>	<u>21</u>
2XXX	<b>Total Liabilities</b>	<u>4,523,450</u>	<u>45</u>	<u>4,458,792</u>	<u>45</u>	<u>4,289,762</u>	<u>44</u>
<b>Equity Attributable to Owners of Parent</b>							
<b>Share Capital</b>							
3110	Ordinary Share	2,980,811	29	2,980,811	30	2,980,811	30
<b>Capital Surplus</b>							
3200	Capital Surplus	643,352	7	642,996	7	642,640	7
<b>Retained Earnings</b>							
3310	Legal Reserve	428,920	4	397,599	4	397,599	4
3320	Special Reserve	188,958	2	188,958	2	188,958	2
3350	Unappropriated Retained Earnings	1,267,100	12	1,216,639	12	1,228,138	12
<b>Other Equity Interest</b>							
3400	Other Interest	44,062	1	53,444	-	55,922	1
3500	Treasury Stock	( 28,054)	-	( 28,054)	-	( 28,054)	-
31XX	<b>Total Equity Attributable to Shareholders of the Parent</b>	<u>5,525,149</u>	<u>55</u>	<u>5,452,393</u>	<u>55</u>	<u>5,466,014</u>	<u>56</u>
36XX	<b>Noncontrolling Interests</b>	<u>38,975</u>	<u>-</u>	<u>45,932</u>	<u>-</u>	<u>49,159</u>	<u>-</u>
3XXX	<b>Total Shareholders' Equity</b>	<u>5,564,124</u>	<u>55</u>	<u>5,498,325</u>	<u>55</u>	<u>5,515,173</u>	<u>56</u>
Significant Contingent Liability&Unrealized Contractual Arrangement							
3X2X	<b>Total Liabilities &amp; Shareholders' Equity</b>	<u>\$ 10,087,574</u>	<u>100</u>	<u>\$ 9,957,117</u>	<u>100</u>	<u>\$ 9,804,935</u>	<u>100</u>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Comprehensive Income(Reviewed, Not Audited)**  
**Nine months Ended September 30, 2017 and 2016**

Unit : NT\$ Thousands  
(EPS: NT Dollars)

Item	For the Three Months Ended September 30				For the Nine Months Ended September 30			
	2	1	2	1	2	1	2	1
	A m o u n t	%	A m o u n t	%	A m o u n t	%	A m o u n t	%
4000 Operating Revenue	\$ 1,524,264	100	\$ 1,385,208	100	\$ 4,559,870	100	\$ 4,353,766	100
5000 Operating Costs	( 1,051,990)	( 69)	( 986,651)	( 71)	( 3,200,710)	( 70)	( 3,074,430)	( 71)
5950 <b>Gross Profit from Operations</b>	<u>472,274</u>	<u>31</u>	<u>398,557</u>	<u>29</u>	<u>1,359,160</u>	<u>30</u>	<u>1,279,336</u>	<u>29</u>
<b>Operating Expenses</b>								
6100 Selling Expenses	( 246,840)	( 16)	( 216,298)	( 16)	( 723,948)	( 16)	( 648,331)	( 15)
6200 Administrative Expenses	( 44,539)	( 3)	( 45,173)	( 3)	( 141,604)	( 3)	( 134,791)	( 3)
6300 Research and Development Expenses	( 90,859)	( 6)	( 80,435)	( 6)	( 253,342)	( 6)	( 238,337)	( 5)
6000 <b>Total Operating Expenses</b>	<u>( 382,238)</u>	<u>( 25)</u>	<u>( 341,906)</u>	<u>( 25)</u>	<u>( 1,118,894)</u>	<u>( 25)</u>	<u>( 1,021,459)</u>	<u>( 23)</u>
6900 <b>Net Operating Income</b>	<u>90,036</u>	<u>6</u>	<u>56,651</u>	<u>4</u>	<u>240,266</u>	<u>5</u>	<u>257,877</u>	<u>6</u>
<b>Non- Operating Income and Expenses</b>								
7010 Other Revenue	7,564	1	9,041	1	37,427	1	33,357	1
7020 Other Gains and Losses	536	-	9,123	1	2,605	-	17,857	-
7050 Finance Cost	( 8,793)	( 1)	( 10,063)	( 1)	( 26,742)	( 1)	( 27,904)	( 1)
7060 Share of Profit or Loss of Associates & Joint Ventures Accounted for Using Equity Method)	32,835	2	16,956	1	53,060	1	63,153	2
7000 <b>Total Non-Operating Income and Expenses</b>	<u>32,142</u>	<u>2</u>	<u>25,057</u>	<u>2</u>	<u>66,350</u>	<u>1</u>	<u>86,463</u>	<u>2</u>
7900 <b>Income Before Income Tax</b>	<u>122,178</u>	<u>8</u>	<u>81,708</u>	<u>6</u>	<u>306,616</u>	<u>6</u>	<u>344,340</u>	<u>8</u>
7950 Income Tax Expense	( 19,797)	( 1)	( 14,646)	( 1)	( 49,617)	( 1)	( 58,438)	( 1)
8200 <b>Net Income</b>	<u>\$ 102,381</u>	<u>7</u>	<u>\$ 67,062</u>	<u>5</u>	<u>\$ 256,999</u>	<u>5</u>	<u>\$ 285,902</u>	<u>7</u>
<b>Other Comprehensive Income that will be Reclassified to Profit or Loss</b>								
8361 Exchange Differences on Translation of Foreign Financial Statements	\$ 23,778	1	(\$ 39,943)	( 3)	(\$ 43,655)	( 1)	(\$ 85,815)	( 2)
8362 Unrealised Gains (Losses) on Valuation of Available-for-sale Financial Assets	5,878	-	( 2,551)	-	27,458	1	( 3,837)	-
8370 Share of Other Comprehensive Income (Loss) of Subsidiaries and Associates Equity Method - Will be Reclassified to Profit	( 1,208)	-	( 324)	-	( 606)	-	( 1,945)	-
8399 Income Tax Relating to Components of Other Comprehensive Income	( 4,042)	-	6,790	-	7,421	-	14,588	-
8360 <b>Total Components of Other Comprehensive Income That Will be Reclassified to Profit or Loss</b>	<u>24,406</u>	<u>1</u>	<u>( 36,028)</u>	<u>( 3)</u>	<u>( 9,382)</u>	<u>-</u>	<u>( 77,009)</u>	<u>( 2)</u>
8300 <b>Net Other Comprehensive Income and Loss After Tax</b>	<u>\$ 24,406</u>	<u>1</u>	<u>(\$ 36,028)</u>	<u>( 3)</u>	<u>(\$ 9,382)</u>	<u>-</u>	<u>(\$ 77,009)</u>	<u>( 2)</u>
8500 <b>Total Comprehensive Income</b>	<u>\$ 126,787</u>	<u>8</u>	<u>\$ 31,034</u>	<u>2</u>	<u>\$ 247,617</u>	<u>5</u>	<u>\$ 208,893</u>	<u>5</u>
<b>Net Income (Losses) Attributable to:</b>								
8610 Shareholders of the Parent	<u>\$ 103,291</u>	<u>7</u>	<u>\$ 67,380</u>	<u>5</u>	<u>\$ 260,631</u>	<u>5</u>	<u>\$ 280,879</u>	<u>7</u>
8620 Non-controlling Interests	<u>(\$ 910)</u>	<u>-</u>	<u>(\$ 318)</u>	<u>-</u>	<u>(\$ 3,632)</u>	<u>-</u>	<u>\$ 5,023</u>	<u>-</u>
<b>Comprehensive Income Attributable to:</b>								
8710 Shareholders of the Parent	<u>\$ 127,697</u>	<u>8</u>	<u>\$ 31,352</u>	<u>2</u>	<u>\$ 251,249</u>	<u>5</u>	<u>\$ 203,870</u>	<u>5</u>
8720 Non-controlling Interests	<u>(\$ 910)</u>	<u>-</u>	<u>(\$ 318)</u>	<u>-</u>	<u>(\$ 3,632)</u>	<u>-</u>	<u>\$ 5,023</u>	<u>-</u>
<b>Earnings per Share</b>								
9750 <b>Diluted Earnings Per Share</b>	<u>\$</u>	<u>0.35</u>	<u>\$</u>	<u>0.23</u>	<u>\$</u>	<u>0.88</u>	<u>\$</u>	<u>0.94</u>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statement of Changes in Equity (Reviewed, Not Audited)**  
**Nine months Ended September 30, 2017 and 2016**

Unit : NT\$ Thousands

	Total Equity Attributable to Owners of Parent										Non-controlling Interests	Total Equity
	Ordinary Share	Additional Paid-In Capital	Treasury Stock Transactions	Legal Reserve	Special Reserve	Unappropriated Retained Earnings	Exchange Differences on Translation	Equity Unrealized Gains(Losses) on Available-for-sale Financial Assets	Treasury Stock	Total		
<b>January 1st to September 30, 2016</b>												
Equity at Beginning Of Period	\$ 2,980,811	\$ 578,416	\$ 64,224	\$ 362,229	\$ 188,958	\$ 1,161,478	\$ 51,707	\$ 81,224	(\$ 28,054 )	\$ 5,440,993	\$ 48,464	\$ 5,489,457
Appropriation and Distribution of Retained Earnings of 2015												
Legal Reserve	-	-	-	35,370	-	( 35,370 )	-	-	-	-	-	-
Cash Dividends	-	-	-	-	-	( 178,849 )	-	-	-	( 178,849 )	-	( 178,849 )
Consolidated Income (Loss)	-	-	-	-	-	280,879	-	-	-	280,879	5,023	285,902
Other Comprehensive Income (Loss)	-	-	-	-	-	-	( 71,372 )	( 5,637 )	-	( 77,009 )	-	( 77,009 )
Changes in Non-controlling Interests	-	-	-	-	-	-	-	-	-	-	( 4,328 )	( 4,328 )
<b>Balance, September 30, 2016</b>	<b>\$ 2,980,811</b>	<b>\$ 578,416</b>	<b>\$ 64,224</b>	<b>\$ 397,599</b>	<b>\$ 188,958</b>	<b>\$ 1,228,138</b>	<b>(\$ 19,665 )</b>	<b>\$ 75,587</b>	<b>(\$ 28,054 )</b>	<b>\$ 5,466,014</b>	<b>\$ 49,159</b>	<b>\$ 5,515,173</b>
<b>January 1st to September 30, 2017</b>												
Equity at Beginning Of Period	\$ 2,980,811	\$ 578,416	\$ 64,580	\$ 397,599	\$ 188,958	\$ 1,216,639	(\$ 542 )	\$ 53,986	(\$ 28,054 )	\$ 5,452,393	\$ 45,932	\$ 5,498,325
Appropriation and Distribution of Retained Earnings of 2016												
Legal Reserve	-	-	-	31,321	-	( 31,321 )	-	-	-	-	-	-
Cash Dividends	-	-	-	-	-	( 178,849 )	-	-	-	( 178,849 )	-	( 178,849 )
Subsidiaries Acquired Cash Dividend Payment of Parent Company	-	-	356	-	-	-	-	-	-	356	-	356
Consolidated Income (Loss)	-	-	-	-	-	260,631	-	-	-	260,631	( 3,632 )	256,999
Other Comprehensive Income (Loss)	-	-	-	-	-	-	( 36,447 )	27,065	-	( 9,382 )	-	( 9,382 )
Changes in Non-controlling Interests	-	-	-	-	-	-	-	-	-	-	( 3,325 )	( 3,325 )
<b>Balance, September 30, 2017</b>	<b>\$ 2,980,811</b>	<b>\$ 578,416</b>	<b>\$ 64,936</b>	<b>\$ 428,920</b>	<b>\$ 188,958</b>	<b>\$ 1,267,100</b>	<b>(\$ 36,989 )</b>	<b>\$ 81,051</b>	<b>(\$ 28,054 )</b>	<b>\$ 5,525,149</b>	<b>\$ 38,975</b>	<b>\$ 5,564,124</b>

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Cash Flows(Reviewed, Not Audited)**  
**Nine months Ended September 30, 2017 and 2016**

Unit : NT\$ Thousands

**For the Nine Months Ended September 30**  
September, 2017      September, 2016

**Cash Flows From (Used in) Operating Activities**

Consolidated Profit (Loss) Before Tax	\$	306,616	\$	344,340
Depreciation expense		186,529		186,483
Amortized Expense		5,047		1,207
Bad Debts Recognized Revenue		2,224		3,547
Decrease in Allowance for Sales Returns and Allowances		10,035	(	2,532)
Interest Expense		26,742		27,904
Interest Revenue	(	11,718)	(	8,425)
Dividend Revenue	(	10,390)	(	9,091)
Share of gain (loss) of Associates and Joint Ventures Accounted for Using Equity Method	(	53,060)	(	63,153)
Gain on Disposal of Property, Plant and Equipment	(	3,405)	(	682)
Notes Receivable (Include Related Parties)		71,351	(	28,178)
Accounts Receivable (Include Related Parties)	(	68,713)	(	6,499)
Other Receivable (Include Related Parties)	(	212)	(	15,908)
Inventories	(	81,587)	(	42,271)
Prepayments	(	61,953)	(	19,154)
Notes Payable		36,126	(	64,529)
Accounts Payable		96,625		46,801
Other Payable	(	62,438)	(	19,458)
Short-term Provision		10,129		9,869
Other Current Liabilities	(	42,907)	(	24,030)
Other Non-Current Liabilities	(	43,835)	(	189,875)
<b>Cash Inflow (Outflow) Generated from Operations</b>		311,206		126,366
Interest Received		11,731		8,708
Interest Paid	(	26,907)	(	28,213)
Income Taxes Paid	(	33,451)	(	27,586)
Income Taxes Refund		18,483		-
Cash Dividends Received		89,600		66,268
<b>Net Cash Flows from (used in) Operating Activities</b>		370,662		145,543

(Continue)

**China Chemical & Pharmaceutical Co., Ltd. And Subsidiaries**  
**Consolidated Statements Of Cash Flows(Reviewed, Not Audited)**  
**Nine months Ended September 30, 2017 and 2016**

Unit : NT\$ Thousands

**For the Nine Months Ended September 30**  
September, 2017      September, 2016

<b><u>Cash Flows From (Used in) Investing Activities</u></b>		
Disposal of Current Investments in Debt Instrument Without		
Active Market	\$           9,000	\$           4,000
Decrease(Increase) in Financing Receivable	1,201	(       22,994 )
Decrease(Increase) in Pledged Deposit	(       9,488 )	14,636
Decrease(Increase) in Refundable Deposits	(       5,131 )	2,622
Decrease(Increase) in Other Non-current Assets	(           543 )	4,573
Purchase of Property, Plant and Equipment	(       112,493 )	(       89,294 )
Disposal of Property, Plant and Equipment	3,960	1,753
Purchase of Intangible Aassets	(           750 )	-
Acquisition of Subsidiaries (Deduct Cash acquired)	-	(       7,783 )
<b>Net Cash Flows From (Used in) Investing Activities</b>	<u>(       114,244 )</u>	<u>(       92,487 )</u>
<b><u>Cash flows from (used in) Financing Activities</u></b>		
Decrease(Increase) In Short-term Borrowings	10,595	16,626
Decrease(Increase) in Short-term Notes and Bills Payable	(       24,508 )	11,000
Proceeds from Long-term Borrowings	555,000	261,000
Repayment of Long-term Borrowings	(       455,000 )	(       142,000 )
Decrease(Increase) in Guarantee Deposits Received	4,038	(       9,968 )
Assigned Cash Dividends	(       178,849 )	(       178,849 )
Acquired Cash Dividends By Minority Interest	(       3,325 )	(       4,328 )
Net cash FlowsFrom (Used in) Financing Activities	<u>(       92,049 )</u>	<u>(       46,519 )</u>
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(       17,696 )	(       23,481 )
Net Increase (Decrease) In Cash and Cash Equivalents	146,673	(       16,944 )
Cash and Cash Equivalents at Beginning of Period	<u>628,746</u>	<u>701,797</u>
Cash and Cash Equivalents at End of Period	<u>\$       775,419</u>	<u>\$       684,853</u>